A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

Keyphrases

• Patients with Advanced Cancer 100%
• Phase I Trial 100%
• Maintenance Dose 100%
• Dosing Schedule 100%
• Loading Dose 100%
• Perifosine 100%
• Sarcoma 66%
• Stable Disease 66%
• Once-daily 66%
• Pharmacokinetic Data 66%
• Daily Maintenance 66%
• Renal Cell Carcinoma 33%
• Signal Transduction Pathway 33%
• Maximum Tolerated Dose 33%
• Dose-limiting Toxicity 33%
• Diarrhea 33%
• Nausea 33%
• Serum Concentration 33%
• Treatment-related Mortality 33%
• Partial Response 33%
• Dose Level 33%
• Clinical Trials 33%
• Chronic Phase 33%
• Starting Dose 33%
• Early Phase Clinical Trials 33%
• Therapeutic Index 33%
• Preclinical Data 33%
• Drug Levels 33%
• Biologically Active 33%
• Gastrointestinal Toxicity 33%
• Loperamide 33%
• Cell Targeting 33%
• Solid Malignancies 33%
• Dehydration 33%
• Difficult to Manage 33%
• Long Half-life 33%
• Membrane Targeting 33%
• 5-HT3 Receptor Antagonist 33%
• Related Compounds 33%
• Multiple Patients 33%
• Hemolytic Properties 33%
• Alkylphosphocholines 33%
• Maintenance Dosing 33%
• Loading Phase 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Advanced Cancer 100%
• Phase I Trials 100%
• Maintenance Dose 100%
• Perifosine 100%
• Diseases 66%
• Clinical Trial 66%
• Pharmacokinetic 66%
• Connective Tissue Cancer 66%
• Renal Cell Carcinoma 33%
• Maximum Tolerated Dose 33%
• Diarrhea 33%
• Nausea 33%
• Dexamethasone 33%
• Therapeutic Window 33%
• Gastrointestinal Toxicity 33%
• Loperamide 33%
• Serotonin 3 Antagonist 33%
• Alkylphosphocholine 33%
• Membrane Targeting 33%